 | Up a level |
Llovet, J; Merle, P; Weiss, KH; Yau, T; Ross, P; Mazzaferro, V; Blanc, JF; Ma, Y; Yen, C; Kocsis, J; Choo, S; Sukeepaisarnjaroen, W; Gerolami, R; Dufour, Jean-François; Gane, E; Ryoo, BY; Peck, M; Dao, T; Yeo, W; Lamlertthon, W; ... (November 2016). Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC). Hepatology, 64(1Suppl), 621A-621A. Wiley Interscience
Bernhard, J; Zahrieh, D; Zhang, J J; Martinelli, G; Basser, R; Hürny, C; Forbes, J F; Aebi, S; Yeo, W; Thürlimann, B; Green, M D; Colleoni, M; Gelber, R D; Castiglione-Gertsch, M; Price, K N; Goldhirsch, A; Coates, A S (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British journal of cancer, 98(1), pp. 25-33. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604092
